Finance

Beta
Lists
MNPR:NASDAQ
Monopar Therapeutics Inc
$97.79
+2.90%
(+2.76) 1D
$97.79
0.00% (0.00)
After hours
Closed: Jul 2, 4:00:01 PM GMT-4  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for MNPR...
Open
$95.44
High
$100.00
Low
$93.59
Mkt. cap
655.10M
Avg. vol.
158.20K
Volume
188.27K
52-wk high
$105.00
52-wk low
$29.18
EPS
-$1.90
Beta
1.46
Shares outstanding
6.70M
No. of employees
22
Open
$95.44
High
$100.00
Low
$93.59
Mkt. cap
655.10M
Avg. vol.
158.20K
Volume
188.27K
52-wk high
$105.00
52-wk low
$29.18
EPS
-$1.90
Beta
1.46
Shares outstanding
6.70M
No. of employees
22
News stories
From sources across the web
About Monopar Therapeutics Inc
CEO-
Employees22
Founded2014
HeadquartersWilmette, Illinois, United States
SectorBiotechnology
Websitemonopartx.com
Analyst ratings
Based on 9 analysts giving stock ratings to MNPR in the past 3 months
Strong buy
Buy
9
Hold
0
Sell
0
12-month forecast
Based on 9 Wall Street analysts offering 12 month price targets for MNPR in the last 3 months.
Highest
Current $97.79
$130.00 (+32.94%)
Average
$113.33 (+15.89%)
Lowest
$101.00 (+3.28%)
Analyst
Recommendation
Action
Price target
Projected
Date
Chad Messer
Lake Street
Buy
Maintained
$103.00
+5.3%
06/30/2026
Jeet Mukherjee
BTIG
Buy
Reiterated
$117.00
+19.6%
07/01/2026
Boris Peaker
JonesTrading
Buy
Maintained
$130.00
+32.9%
06/29/2026
Biren Amin
Piper Sandler
Buy
Maintained
$101.00
+3.3%
06/29/2026
Andres Y. Maldonado
H.C. Wainwright
Buy
Reiterated
$105.00
+7.4%
06/29/2026
Etzer Darout
Barclays
Buy
Maintained
$125.00
+27.8%
06/29/2026
Maxwell Skor
Morgan Stanley
Buy
Maintained
$115.00
+17.6%
05/18/2026
Unknown Analyst
Leerink Partners
Buy
Reiterated
$115.00
+17.6%
05/15/2026
Kristen Kluska
Cantor Fitzgerald
Buy
Maintained
$109.00
+11.5%
05/14/2026
Soumit Roy
JonesTrading
Buy
Maintained
$130.00
+32.9%
04/06/2026
Previous reportsAll values in USD
Loading Previous Earnings...
Income statement
Revenue
Net income
All values in USD
Jun 2025
Sep 2025
Dec 2025
Mar 2026
Revenue
-
-
-
-
Cost of goods sold
-
-
-
-
Cost of revenue
-
-
-
-
Research and development expenses
1.73M
2.59M
3.94M
3.49M
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
1.50M
1.50M
2.21M
1.74M
Operating expense
3.23M
4.09M
6.16M
5.23M
Total operating expenses
3.23M
4.09M
6.16M
5.23M
Operating income
-3.23M
-4.09M
-6.16M
-5.23M
Other non operating income
-
1.00
-1.00
-
EBT including unusual items
-2.45M
-3.44M
-5.20M
-3.89M
EBT excluding unusual items
-2.45M
-3.44M
-5.20M
-3.89M
Income tax expense
-
-
-
-
Effective tax rate
-
-
-
-
Other operating expenses
-
-
-
-
Net income
-2.45M
-3.44M
-5.20M
-3.89M
Net profit margin
-
-
-
-
Earnings per share
-0.35
-0.48
-0.61
-0.46
Interest and investment income
780.77K
655.47K
954.43K
1.33M
Interest expense
-
-
-
-
Net interest expenses
780.77K
655.47K
954.43K
1.33M
Depreciation and amortization charges
-
-
-
-
EBITDA
-
-
-
-
Gain or loss from assets sale
-
-
-
-
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer

Research

What's on your mind?
What's going on with the markets today?
Explore what’s possible
Deep Search
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer